www.StockMarketingInc.com: Our Newsletter Is On Fire!! Sign Up Now!! DPTR,GFRE,GNVC,HEV,LGND,JUNP

Fri. November 06, 2009; Posted: 10:56 AM

(NASDAQ: DPTR - Delta Petroleum Corp.)

(NASDAQ: GFRE - Gulf Resources, Inc.)

(NASDAQ: GNVC - GenVec, Inc.)

(NASDAQ: HEV - Ener1, Inc.)

(NASDAQ: LGND - Ligand Pharmaceuticals Incorporated)

(OTCBB: JUNP - Juniper Group, Inc.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: DPTR - Delta Petroleum Corp.)

LATEST NEWS!!

Delta Petroleum Corporation Announces Third Quarter 2009 Operating Results

DENVER, Nov 05, 2009 -- Delta Petroleum Corporation (Nasdaq: DPTR), an independent oil and gas exploration and development company, announced its financial and operating results for the third quarter of 2009.

GRAY 31-23 COMPLETION RESULTS Delta has finished completion efforts on the Gray well. As previously announced, while all zones encountered significant high pressure, they flowed primarily water with minor amounts of non-commercial associated gas. Additional testing was performed in the basalt section of the well with a similar outcome, and therefore the Gray well has been expensed as a dry hole in the Company's third quarter financial statements.

Delta's Columbia River Basin team has reviewed available data in order to provide possible explanations regarding the lack of commercial gas from the Wenatchee sands of the Gray well. One of the challenges generally experienced in the industry is the fact that fresh water and hydrocarbons are almost indistinguishable on electric logs. Therefore the gas shows and over-pressured reservoir seen in the Gray well during drilling suggested a gas reservoir with some associated water; however, completion results instead revealed that the reservoir is a fresh water reservoir with some associated natural gas.

The lessons learned from the drilling of the Gray well have provided the Company with important and strategic information that will be of benefit in any future drilling operations in the Columbia River Basin. Numerous issues related to drilling through the basalt formation were identified, analyzed and explained, and management believes that this information can be translated into potentially significant savings of both cost and time in the future. While gas was liberated, no source rock was drilled in this well, thus Delta's primary objective, the deeper Roslyn formation, remains a viable target.

John Wallace, the Company's President and COO said, "We are extremely disappointed with the results of the Gray well, but exploration drilling carries with it significant risks. We continue to believe that the Roslyn formation, which has produced elsewhere in the Columbia River Basin, has significant potential and should be tested. In addition, data obtained during the drilling of the Gray well has allowed for better seismic interpretation that can now be applied to the Company's leasehold in the basin. A more accurate representation of the structural configuration below the basalt section, including the Roslyn formation, will help direct us to more precise geologic prospects and potential future well locations." "While much attention was paid to the drilling and completion of the Gray well, we want to highlight to our stockholders where the intrinsic value lies within Delta. Delta's operational strength is in the Rockies and go forward strategy focused on lower-risk development projects will allow the Company to realize consistent, efficient reserve and production growth in the Piceance Basin, once natural gas prices recover. We believe that we have the track record, experience and assets that will allow us to execute this strategy." Dan Taylor, the Company's Chairman stated, "Delta will continue to strive to deliver value to our shareholders through the development of our core assets and the execution of our cost control strategy. I concur with John on the underlying value of Delta being our proved and probable reserves in the Piceance Basin, which are not adequately reflected in our current share price."

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: GFRE - Gulf Resources, Inc.)

LATEST NEWS!!

Gulf Resources Announces Conference Call to Discuss Third Quarter 2009 Results

NEW YORK and SHANDONG, China, Nov 05, 2009 -- Gulf Resources, Inc. (Nasdaq: GFRE) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that the Company will host a conference call on Tuesday, November 10, 2009 at 8:00 AM Eastern Standard Time to discuss its financial results for the third quarter 2009 ended September 30, 2009.

Hosting the call will be Mr. Xiaobin Liu, CEO of Gulf Resources and Mr. David Wang, VP Finance of Gulf Resources. In addition, Mr. Crocker Coulson, President of CCG Investor Relations, the Company's investor relations firm, will serve as a speaker during the call.

To participate in this live conference call, please dial 888-419-5570 five to ten minutes prior to the scheduled conference call time. International callers should call +1 617-896-9871. The conference participant pass code is 106 766 49.

A replay of the conference call will be available for 14 days starting from 10:00 AM Eastern Standard Time on Tuesday, November 10, 2009. To access the replay, call 888-286-8010. International callers should call +1 617-801- 6888. The pass code is 60534507. A replay of the call will also be made available in the investor relations section of the Company's website at http://www.gulfresourcesinc.cn .

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: GNVC - GenVec, Inc.)

LATEST NEWS!!

GenVec Signs New Contract to Support HIV and Influenza Vaccine Development

GAITHERSBURG, Md., Nov 05, 2009 -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) Under the contract, the vaccines would be comprised of genetic material supplied by the VRC and adenoviral vectors supplied by GenVec.

"This new contract supports important efforts in HIV and influenza. Given the heightened concerns about influenza, this contract is timely and we look forward to applying our novel technology to this problem," stated Dr. Paul Fischer, GenVec's President and CEO. "In particular, we are looking forward to working on a universal flu vaccine, which has the potential to protect against seasonal and pandemic outbreaks." Work under this contract will include generation of HIV vaccine candidates, generation of a universal flu vaccine candidate, process and assay development for manufacture of vaccine candidates for clinical testing, and continued support of the HIV vaccine candidates currently in clinical testing.

About GenVec GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product TNFerade is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: HEV - Ener1, Inc.)

LATEST NEWS!!

EnerDel Wins U.S. Army Contract to Develop Batteries for New 'Hybrid Humvee'

--Program Will Test EnerDel's High-Performance Solutions Under the Most Extreme Conditions

INDIANAPOLIS, Nov 05, 2009 -- Automotive lithium-ion battery maker EnerDel, Inc. announced today that it will be working with the United States Army to develop a next-generation battery system for the hybrid version of the iconic High Mobility Multipurpose Wheeled Vehicle (HMMWV or Humvee), known as the XM1124 Humvee. The company, a subsidiary of Ener1, Inc. (Nasdaq: HEV), has received a $1.29 million contract to design and build high-performance lithium-ion battery systems for two different applications, drawing on its expertise in multiple-chemistry solutions and ability to provide a complete architecture in cell chemistry, electronics and battery systems design.

"This is an opportunity to showcase the true capabilities of the EnerDel technology in conditions that demand the highest levels of safety, performance and reliability," said Rick Stanley, EnerDel President. "In keeping with a long tradition, we also expect that innovations perfected here will have important benefits for the commercial markets." EnerDel will spend the next 18 months collaborating with the U.S. Army Tank Automotive Research, Development and Engineering Center (TARDEC) to produce four custom-built power systems that will be subjected to extreme performance simulations.

TARDEC will be testing two of EnerDel's battery chemistries. In addition to its lithium-manganese spinel chemistry, best suited for extending electric vehicle range or electronic systems runtime, the program will also be testing EnerDel's lithium-titanate system, an advanced chemistry developed in collaboration with Argonne National Laboratory in Chicago, designed for extreme high-power hybrids that require hard acceleration and braking.

While the XM1124 Humvee is already significantly more efficient than the conventional M1113 Humvee, boasting a higher top speed, faster acceleration, longer range and improved fuel economy, expectations are that the new, upgraded battery packs will greatly increase the peak power capability of the current demonstration vehicles.

In addition, the robust battery technology will also include an all-electric "silent watch" capability which will power the electronics or traction motor without running the truck's diesel generator, significantly reducing both the audible and thermal signatures of the vehicle, making it easier to escape detection by hostile parties. An EnerDel-equipped XM1124 Humvee could also function as a portable power plant to power a mobile command post or field hospital.

TARDEC, part of the U.S. Army Research, Development and Engineering Command (RDECOM), is headquartered at the Detroit Arsenal in Warren, Michigan. It is the nation's laboratory for advanced military automotive technology. TARDEC develops and integrates technology solutions to improve the effectiveness of the current force and realize the superior capability of the future force. Its technical staff leads research in ground vehicle survivability, mobility, intelligent systems and maneuver support and sustainment.

The TARDEC award further spurs Ener1's business momentum. The company has announced active relationships with Think Global, Fisker and Volvo and has a research program with Nissan and Argonne National Laboratory. Ener1 was recently selected to be awarded a $118.5 million grant from the U.S. Department of Energy under the Federal Stimulus program and is awaiting approval of additional long-term, low-interest loan funds under the Department's Advanced Technology Vehicle Manufacturing program. EnerDel's two factories in Indianapolis are the first, and so far only, commercial-scale, automotive-grade lithium-ion battery manufacturing facilities in the United States.

About Ener1, Inc.

Ener1 develops and manufactures compact, high performance lithium-ion batteries to power the next generation of hybrid, plug-in hybrid and pure electric vehicles. The publicly traded company (Nasdaq: HEV) is led by an experienced team of engineers and energy system experts at its EnerDel subsidiary located in Indiana. In addition to the automobile market, applications for Ener1 lithium-ion battery technology include the military, grid storage and other growing markets. Ener1 also develops commercial fuel cell products through its EnerFuel subsidiary and nanotechnology-based materials and manufacturing processes for batteries and other applications through its NanoEner subsidiary.

Safe Harbor Statement

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: LGND - Ligand Pharmaceuticals Incorporated)

LATEST NEWS!!

Ligand's JAK3 Research Collaboration Extended by Pfizer

SAN DIEGO, Nov 05, 2009 -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization. Under the original agreement, Ligand is entitled to receive up to $175 million in milestone payments for the successful development and commercialization of multiple products. In addition, Ligand will receive royalties on product sales.

"We are very pleased to learn that Pfizer has elected to extend the JAK3 research collaboration with Ligand," said John L. Higgins, President and Chief Executive Officer of Ligand. "We view JAK3 inhibitors as a very promising market opportunity, and given Pfizer's clinical success with its own internal program we are convinced that they are highly committed to this category. Ligand has an exceptional record of drug discovery while serving major pharmaceutical companies in a number of research collaborations. We are pleased with the team's progress and look forward to continued success as we drive the program forward for Pfizer." About JAK3 JAK3 is a tyrosine kinase that belongs to the Janus family of enzymes, and it is an important target for therapeutic interventions in the treatment of autoimmune disorders, inflammation, and organ transplant rejections. JAK3 expression seems to be limited to hematopoietic cells, and specific inhibitors of JAK3 could represent a new class of immunosuppressant drugs.

About Ligand Pharmaceuticals Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases, anemia, asthma, rheumatoid arthritis and psoriasis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, Pfizer and Wyeth Pharmaceuticals (now Pfizer). With nine pharmaceutical agreements and more than 20 molecules in various stages of development, Ligand utilizes proprietary technologies for identifying drugs with novel receptor and enzyme drug targets.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: JUNP - Juniper Group, Inc.)

LATEST NEWS!!

Juniper Opens Kentucky Market

BOCA RATON, FL, Nov 05, 2009 -- Juniper Group, Inc. (OTCBB:JUNP) announced today that its wholly-owned telecommunications subsidiary has been asked to enlarge the footprint of its Midwest market to include the state of Kentucky.

The work being performed for this particular customer is once again supporting the growth of their 3G network, already considered one of the fastest in the nation. Particulars include the continued enhancements of local 2G technology and subsequent upgrades to 3G in this market.

Vlado P. Hreljanovic, President and CEO said, "We are most proud of our teams of technicians and administrators, as our continued growth and expanded market share is due in large part to their diligence and excellence. We continue to strive for complete customer satisfaction."

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index